Fulcrum Therapeutics (FULC) Receivables - Accured (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Receivables - Accured for 9 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Receivables - Accured rose 60.47% year-over-year to $2.0 million; the TTM figure through Jun 2026 stood at $2.0 million (up 60.47% YoY), while the FY2025 annual figure was $1.1 million, down 14.13% from the prior year.
• Receivables - Accured rose to $2.0 million in Q2 2026 per FULC's latest filing, from $1.8 million in the prior quarter.
• Across five years, Receivables - Accured topped out at $2.0 million in Q2 2026 and bottomed at $392000.0 in Q2 2022.
• Historically, Receivables - Accured has averaged $1.2 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Accured soared 298.04% — and 2025, when it sank 40.66%.
• Fulcrum Therapeutics' Receivables - Accured stood at $852000.0 in 2022, then surged by 100.94% to $1.7 million in 2023, then fell by 27.22% to $1.2 million in 2024, then fell by 14.13% to $1.1 million in 2025, then soared by 89.72% to $2.0 million in 2026.
• Business Quant data shows FULC's Receivables - Accured at $2.0 million in Q2 2026, $1.8 million in Q1 2026, and $1.1 million in Q4 2025.